Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + trastuzumab + erlotinib
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triplet combination therapy consisting of gemcitabine (a nucleoside analog chemotherapy agent), trastuzumab (a monoclonal antibody targeting HER2), and erlotinib (a tyrosine kinase inhibitor targeting EGFR). This combination has been studied in clinical trials for the treatment of metastatic pancreatic cancer, showing effectiveness in terms of disease control rate, progression-free survival, and overall survival. The combination works through multiple mechanisms: gemcitabine interferes with DNA synthesis, trastuzumab targets HER2-expressing cancer cells, and erlotinib blocks EGFR signaling.
- Other names
- Gemcitabine-Trastuzumab-ErlotinibGATE 1 regimenGATE1 regimenGATE-1 regimen
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on gemcitabine + trastuzumab + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + trastuzumab + erlotinib.